Editorial update: November 11, 2026 · Health Connect Alliance editorial team.
Sources checked: November 11, 2026.
Professional medical review pending.
If your question is about weight loss medication and anxiety, separate what the research studied from what you are experiencing. Use this guide to prepare questions for your existing care team, including which findings apply to your medicine and which questions remain unanswered.
What the Research Shows
A selected trial population
A post hoc analysis revisited STEP 1, 2, 3 and 5: weight-management trials comparing weekly injected semaglutide 2.4 mg with placebo alongside lifestyle support. Reports of anxiety-related adverse events were broadly similar between groups. Participants had overweight or obesity; STEP 2 also included diabetes. People with recent major depression, other severe psychiatric illness, high depression-screening scores, a past suicide attempt or recent high-risk suicidal thoughts were excluded. The results therefore do not settle risk for those groups or for every GLP-1 medicine.
Novo Nordisk funded the analysis and writing support and took part in design, data analysis and manuscript work. Several authors disclosed company employment, shareholdings or other industry ties. This was not an anxiety-treatment trial.
A different kind of study
A Taiwan insurance-record study compared adults with diabetes using liraglutide, dulaglutide or exenatide with matched nonusers. It reported an association with fewer anxiety diagnoses. It did not study semaglutide or tirzepatide, randomize treatment, or show that weight loss caused a mood change. Missing information included weight change and factors such as stress, smoking and diet, leaving possible confounding. The findings cannot establish a treatment for anxiety.
Support came from Taiwanese government programs, China Medical University Hospital and the Tseng-Lien Lin Foundation. The authors declared no commercial or financial conflicts.
Four Concerns to Bring to Your Care Team
Hormones and Symptom Timing
What changed, and when? Write down the symptoms, medication name and recent prescription changes. Ask what your clinician wants to assess before attributing your experience to a hormonal adjustment.
Blood Sugar Concerns
If blood sugar is one of your concerns, bring that question and any existing monitoring plan to the prescriber. Ask which observations to record and who should interpret them; this article does not set a testing or eating regimen.
Relationship with Food
Describe any distress around appetite, meals or changes in your routine in your own words. Ask whether your current care plan addresses those concerns and whom you can contact between appointments.
Physical Side Effects
Bring physical symptoms and mood concerns to the same conversation. Include when each began and how it affects your day, without assuming one explains the other.
Managing Mental Health on GLP-1s
Maintain Support Systems
Stay connected with friends, family, or support groups. Weight loss journeys can be emotional, and support helps.
Coordinate Existing Mental Health Care
If you already have a therapist or prescribing mental-health clinician, tell them which weight-management medicine you take and ask how to coordinate concerns with the prescriber. Bring your questions to those professionals before making prescription changes.
When to Get Help
Tell your healthcare provider promptly about new, worsening or persistent anxiety, panic attacks or depression. If you have thoughts of self-harm or cannot stay safe, seek urgent help immediately.
What Changed in the Product Labels?
Wegovy lists removal of its warning about suicidal thoughts and behavior in January 2026. Zepbound lists the same change in February 2026. These product-specific histories do not establish absence of anxiety risk or benefit for treating anxiety.